
    
      Albumin-bound paclitaxel plus carboplatin regimen in advanced NSCLC especially in lung
      squamous cell carcinoma has a better tumor response rate and safety, therefore, this program
      is applied to neoadjuvant therapy, may obtain better tumor pathological remission rate,
      improve the operation resection rate, thus improve the prognosis.The main purpose of this
      study is to observe the safety and efficacy of albumin-bound paclitaxel / carboplatin in the
      treatment of lung squamous cell carcinoma of stage IIB and IIIA.
    
  